Arcus Biosciences Stock Fair Value – Arcus Biosciences Unveils Potential of TIGIT for Therapeutic Development
December 16, 2023
🌥️Trending News
Arcus Biosciences ($NYSE:RCUS) has unveiled the potential of TIGIT for therapeutic development. This is a major development within the pharmaceutical sector, and could potentially revolutionize the way treatments are created for serious diseases and conditions. TIGIT is an innovative immuno-oncology target, and is a receptor which plays an important role in the regulation of the immune response. Arcus Biosciences is currently researching ways to leverage TIGIT, and is exhibiting the immense potential of this breakthrough. Arcus Biosciences is a clinical-stage biopharmaceutical company based in California.
It was recently listed on the Nasdaq Global Select Market, and is focused on discovering and developing therapeutics to treat cancer and other serious diseases. The company is leveraging its platform, which combines small molecules, antibodies, and bispecific molecules, in order to develop treatments that are highly impactful. Arcus Biosciences is continuing to make significant progress in the industry, and its dedication to researching new treatments for serious diseases is admirable.
Share Price
The stock opened at $17.7 and closed at $18.1, up by 2.8% from the prior closing price of 17.6. This news was met with enthusiasm among investors and analysts alike, who are interested in the company’s ability to develop a novel drug candidate that could address a number of diseases. TIGIT is a receptor involved in the immune system and has been found to be particularly important in regulating T-cell activation and proliferation.
Therefore, it is a potentially valuable target for drug development due to its role in many different conditions, including cancer, autoimmune diseases, and infectious diseases. The potential of TIGIT combined with ARCUS BIOSCIENCES’ strong research capabilities makes it an exciting prospect for therapeutic development. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Arcus Biosciences. More…
| Total Revenues | Net Income | Net Margin |
| 120 | -293 | -244.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Arcus Biosciences. More…
| Operations | Investing | Financing |
| -288 | 213 | 41 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Arcus Biosciences. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.19k | 671 | 6.95 |
Key Ratios Snapshot
Some of the financial key ratios for Arcus Biosciences are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 15.6% | – | -237.5% |
| FCF Margin | ROE | ROA |
| -255.0% | -32.8% | -15.0% |
Analysis – Arcus Biosciences Stock Fair Value
GoodWhale has conducted an analysis of the wellbeing of ARCUS BIOSCIENCES. Our proprietary Valuation Line has calculated the fair value of ARCUS BIOSCIENCES’ share to be around $23.5. Currently, the stock is being traded at $18.1, which is undervalued by 22.9%. We believe that with good corporate governance and thoughtful decisions, ARCUS BIOSCIENCES can increase its value and benefit its stockholders in the long run. More…
Peers
The company’s product candidates include AB928, AB154 and AB122, which are in various clinical trials for the treatment of solid tumors and hematologic malignancies. Arcus Biosciences Inc’s competitors include Immunic Inc, G1 Therapeutics Inc, Ocuphire Pharma Inc.
– Immunic Inc ($NASDAQ:IMUX)
The company’s market cap is $56.93M as of 2022 and its ROE is -44.31%. The company is engaged in the development of immunotherapies for the treatment of cancer.
– G1 Therapeutics Inc ($NASDAQ:GTHX)
G1 Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapies for the treatment of cancer. The company’s lead product candidate is trilaciclib, which is in clinical development for the treatment of small cell lung cancer (SCLC) and triple-negative breast cancer (TNBC). Trilaciclib is a first-in-class cyclin-dependent kinase 4/6 (CDK4/6) inhibitor that selectively targets proliferating cancer cells and spares normal cells. CDK4/6 inhibitors are a new class of anti-cancer drugs that block the activity of two proteins that are involved in cell division.
G1 Therapeutics has a market cap of $366.9 million and a return on equity of -159.15%. The company’s lead product candidate is trilaciclib, which is in clinical development for the treatment of small cell lung cancer (SCLC) and triple-negative breast cancer (TNBC). Trilaciclib is a first-in-class cyclin-dependent kinase 4/6 (CDK4/6) inhibitor that selectively targets proliferating cancer cells and spares normal cells. CDK4/6 inhibitors are a new class of anti-cancer drugs that block the activity of two proteins that are involved in cell division.
– Ocuphire Pharma Inc ($NASDAQ:OCUP)
Ocuphire Pharma Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing therapies to treat ocular disorders. Its lead product candidate is Nyxol, a once-daily eye drop for the treatment of glaucoma and ocular hypertension. The company was founded by Derek J. Rappaport and Nancy S. Lurie on March 1, 2006 and is headquartered in Boca Raton, FL.
Summary
Arcus Biosciences is a biopharmaceutical company with a focus on cancer immunotherapy. The company’s primary product is its TIGIT antagonist, which has the potential to create a new class of cancer treatments. In recent investing analysis, Arcus Biosciences has seen significant growth, and many analysts are positive about its potential.
They cite the company’s strong pipeline of products, its extensive R&D capabilities and its financial stability as factors that could lead to long-term success. With its strong fundamentals, Arcus is well-positioned to capitalize on its potential and build a sustainable business.
